The Week in Review: Jan 6, 2017 – Jan 13, 2017

Friday, January 13, 2017 News Recap Close to Home This last week has seen some pretty sad news for Canadians with Hep C.  As you know, the Past Economic Loss and Dependents (PELD) Fund of the Pre-1986/Post-1990 Hepatitis C Settlement has a shortfall – with more than $65 million in unpaid claims. On December 15, 2016, a joint hearing was held in Toronto before the judges of Alberta, British Columbia, Ontario and Quebec to discuss the status of the...

Health Canada Approves DAKLINZA™ (daclatasvir) for Difficult-to-Treat Hepatitis C Patient Populations

DAKLINZA™ is approved in Canada in combination with other agents for the treatment of chronic hepatitis C Patients with HIV co-infection, advanced cirrhosis and post-liver transplant HCV recurrence MONTREAL, May 24, 2016 /CNW/ - Bristol-Myers Squibb Canada today announced Health Canada's approval of DAKLINZA™ (daclatasvir), in combination with sofosbuvir (with or without ribavirin) for 12 weeks in the treatment of chronic hepatitis C (CHC) in adult patie

FDA Approves Expanded Use of Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C

Updated label provides new treatment option for patients with HIV-1 coinfection, advanced cirrhosis, and post-liver transplant HCV recurrenceFriday, February 5, 2016 12:47 pm EST--PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) announced today that Daklinza™ (daclatasvir, 60 mg), an NS5A replication complex inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) in combination with sofosbuvir (with or without r